2012
Normalized CCND1 expression has prognostic value in mantle cell lymphoma
Siddon AJ, Torres R, Rinder HM, Smith BR, Howe JG, Tormey CA. Normalized CCND1 expression has prognostic value in mantle cell lymphoma. British Journal Of Haematology 2012, 158: 551-553. PMID: 22671703, DOI: 10.1111/j.1365-2141.2012.09181.x.Peer-Reviewed Original Research
2009
The utility of flow cytometric immunophenotyping in cytopenic patients with a non-diagnostic bone marrow: A prospective study
Truong F, Smith BR, Stachurski D, Cerny J, Medeiros LJ, Woda BA, Wang A. The utility of flow cytometric immunophenotyping in cytopenic patients with a non-diagnostic bone marrow: A prospective study. Leukemia Research 2009, 33: 1039-1046. PMID: 19232722, DOI: 10.1016/j.leukres.2009.01.012.Peer-Reviewed Original ResearchConceptsMyelodysplastic syndromeCytopenic patientsFlow cytometricPredictive valueGroup 1 patientsGroup 2 patientsHematology outpatient clinicBone marrow aspirateNegative predictive valuePositive predictive valueFCM resultsMedian followMyelomonocytic maturationAbnormal cytogeneticsBM examinationBM diseaseClinical entityOutpatient clinicProspective studyMedical causesMorphological dysplasiaClinical managementMarrow aspiratesIdiopathic cytopeniaPatients
2008
DNA ploidy analysis as an adjunct for the detection of relapse in B-lineage acute lymphoblastic leukemia
Kenney B, Zieske A, Rinder H, Smith B. DNA ploidy analysis as an adjunct for the detection of relapse in B-lineage acute lymphoblastic leukemia. Leukemia & Lymphoma 2008, 49: 42-48. PMID: 18203010, DOI: 10.1080/10428190701760052.Peer-Reviewed Original ResearchConceptsAcute lymphoblastic leukemiaDetection of relapseDNA ploidy analysisLymphoblastic leukemiaPloidy analysisB-lineageB-lineage acute lymphoblastic leukemiaCytometric DNA ploidy analysisDiagnosis of relapseNormal precursor B cellsPrecursor B cellsOriginal immunophenotypeRelapsed diseaseUnique immunophenotypeLeukemic immunophenotypesImmunophenotypic detectionRelapseB cellsPatientsImmunophenotypeFlow immunophenotypingFlow cytometryAneuploid populationsDiagnosisLeukemia
2004
Real-time quantitative RT-PCR identifies distinct c-RET, RET/PTC1 and RET/PTC3 expression patterns in papillary thyroid carcinoma
Rhoden KJ, Johnson C, Brandao G, Howe JG, Smith BR, Tallini G. Real-time quantitative RT-PCR identifies distinct c-RET, RET/PTC1 and RET/PTC3 expression patterns in papillary thyroid carcinoma. Laboratory Investigation 2004, 84: 1557-1570. PMID: 15502856, DOI: 10.1038/labinvest.3700198.Peer-Reviewed Original ResearchAdultCarcinoma, PapillaryChildExonsFemaleGene Expression Regulation, NeoplasticHumansMaleMiddle AgedNuclear Receptor CoactivatorsOncogene ProteinsOncogene Proteins, FusionPolymerase Chain ReactionProtein-Tyrosine KinasesProto-Oncogene ProteinsProto-Oncogene Proteins c-retReceptor Protein-Tyrosine KinasesReverse Transcriptase Polymerase Chain ReactionRNA, MessengerThyroid NeoplasmsTranscription Factors
2003
Neutrophil CD11b upregulation during cardiopulmonary bypass is associated with postoperative renal injury
Rinder CS, Fontes M, Mathew JP, Rinder HM, Smith BR, Group M. Neutrophil CD11b upregulation during cardiopulmonary bypass is associated with postoperative renal injury. The Annals Of Thoracic Surgery 2003, 75: 899-905. PMID: 12645714, DOI: 10.1016/s0003-4975(02)04490-9.Peer-Reviewed Original ResearchMeSH KeywordsAcute Kidney InjuryAdultAgedCardiopulmonary BypassCD11b AntigenCoronary Artery BypassCreatinineHeart FailureHeart Valve Prosthesis ImplantationHemodynamicsHumansIntra-Aortic Balloon PumpingLeukocyte CountMiddle AgedNeutrophilsPostoperative ComplicationsProspective StudiesRisk FactorsSystemic Inflammatory Response SyndromeConceptsAcute renal injuryNeutrophil CD11b upregulationRenal injuryCardiopulmonary bypassInflammatory responseCD11b upregulationAdult respiratory distress syndromeMarkers of leukocytesPlatelet CD62P expressionPostoperative hemodynamic supportPostoperative renal injuryNeutrophil inflammatory responseSystemic inflammatory responseRespiratory distress syndromeSubset of patientsC-reactive proteinTotal neutrophil countMonocyte CD11bRenal riskHemodynamic instabilityInflammatory markersPost-CPBHemodynamic supportMyeloperoxidase levelsNeutrophil count
2002
Platelet PlA2 Polymorphism and Platelet Activation Are Associated with Increased Troponin I Release after Cardiopulmonary Bypass
Rinder CS, Mathew JP, Rinder HM, Howe J, Fontes M, Crouch J, Pfau S, Patel P, Smith BR. Platelet PlA2 Polymorphism and Platelet Activation Are Associated with Increased Troponin I Release after Cardiopulmonary Bypass. Anesthesiology 2002, 97: 1118-1122. PMID: 12411794, DOI: 10.1097/00000542-200211000-00013.Peer-Reviewed Original ResearchConceptsTroponin I concentrationsPlatelet glycoprotein IIIaCardiopulmonary bypassPlA2 polymorphismPlA2 alleleI concentrationsMyocardial injuryGlycoprotein IIIaPlatelet activationElective coronary artery bypassHigher troponin I concentrationsPostoperative troponin I concentrationsTroponin IPerioperative myocardial injuryCoronary artery bypassProthrombotic risk factorsCardiopulmonary bypass surgerySevere myocardial injuryArtery bypassBypass surgeryPlatelet polymorphismsRisk factorsCardiovascular settingsPlA2 genotypeBypassReticulated platelets predict platelet count recovery following chemotherapy
Wang C, Smith BR, Ault KA, Rinder HM. Reticulated platelets predict platelet count recovery following chemotherapy. Transfusion 2002, 42: 368-374. PMID: 11961244, DOI: 10.1046/j.1537-2995.2002.00040.x.Peer-Reviewed Original ResearchConceptsPlatelet count recoveryPercentage of RPProphylactic platelet transfusionsCount recoveryPlatelet transfusionsPlatelet recoveryStress thrombopoiesisPlatelet count increaseIdiopathic thrombocytopenic purpuraPlatelet count nadirsChemotherapy-induced thrombocytopeniaNegative predictive valueEvaluable patientsMarrow suppressionThrombocytopenic purpuraChemotherapy patientsThrombocytopenia patientsLower percentagePatientsPredictive valueReproducible indexThrombocytopeniaTransfusionChemotherapyIncreased percentage
2000
Isolation and flow cytometric analysis of T‐cell‐depleted CD34+ PBPCs
Debelak J, Shlomchik M, Snyder E, Cooper D, Seropian S, McGuirk J, Smith B, Krause D. Isolation and flow cytometric analysis of T‐cell‐depleted CD34+ PBPCs. Transfusion 2000, 40: 1475-1481. PMID: 11134567, DOI: 10.1046/j.1537-2995.2000.40121475.x.Peer-Reviewed Original Research
1999
Use of rituximab and irradiated donor-derived lymphocytes to control Epstein–Barr virus-associated lymphoproliferation in patients undergoing related haplo-identical stem cell transplantation
McGuirk J, Seropian S, Howe G, Smith B, Stoddart L, Cooper D. Use of rituximab and irradiated donor-derived lymphocytes to control Epstein–Barr virus-associated lymphoproliferation in patients undergoing related haplo-identical stem cell transplantation. Bone Marrow Transplantation 1999, 24: 1253-1258. PMID: 10642818, DOI: 10.1038/sj.bmt.1702052.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntibodies, MonoclonalAntibodies, Monoclonal, Murine-DerivedAntigens, ViralAntineoplastic AgentsBlood Component TransfusionBlood DonorsDNA, ViralGraft vs Host DiseaseHematologic NeoplasmsHematopoietic Stem Cell TransplantationHerpesvirus 4, HumanHumansImmunosuppression TherapyLymphocytesLymphoproliferative DisordersMalePolymerase Chain ReactionRituximabConceptsEpstein-Barr virus-associated lymphoproliferative disorderStem cell transplantationEBV DNA titersB cell populationsCell transplantationTherapeutic strategiesEpstein-Barr virus-associated lymphoproliferationHaplo-identical stem cell transplantationEffective alternative therapeutic strategyAllogeneic stem cell transplantationCourses of rituximabDonor-derived lymphocytesPost-transplant immunosuppressionMonoclonal B-cell populationCD20 monoclonal antibodyCell populationsAlternative therapeutic strategiesImmunosuppressive medicationsSevere GVHDHost diseaseLymphocyte infusionPost transplantFatal complicationCurative therapyLymphoproliferative disordersCyclophosphamide, cytosine arabinoside and TBI as a conditioning regimen for allogeneic bone marrow transplantation in patients with leukemia
Jillella A, Doria R, Khan K, Zelterman D, Ahmad Y, Smith B, Holmes W, Becker P, Roberts K, Rappeport J. Cyclophosphamide, cytosine arabinoside and TBI as a conditioning regimen for allogeneic bone marrow transplantation in patients with leukemia. Bone Marrow Transplantation 1999, 23: 1095-1100. PMID: 10382947, DOI: 10.1038/sj.bmt.1701786.Peer-Reviewed Original ResearchConceptsAllogeneic bone marrow transplantationTotal body irradiationBone marrow transplantationConditioning regimenMarrow transplantationMyeloablative regimenRelapse rateBody irradiationHematologic malignanciesAntileukemic effectGood prognosis diseaseHigh-dose cytosineHost disease (GVHD) prophylaxisShort-course methotrexateEvidence of diseaseOverall relapse rateHigh-dose AraPoor prognosis diseaseKaplan-Meier estimatesActuarial survivalConditioning regimensDisease prophylaxisMyeloablative regimensProspective studyRegimen
1998
Correlation of Thrombosis With Increased Platelet Turnover in Thrombocytosis
Rinder H, Schuster J, Rinder C, Wang C, Schweidler H, Smith B. Correlation of Thrombosis With Increased Platelet Turnover in Thrombocytosis. Blood 1998, 91: 1288-1294. PMID: 9454759, DOI: 10.1182/blood.v91.4.1288.Peer-Reviewed Original ResearchConceptsRP countsNormal platelet countPlatelet countThrombocytosis patientsPlatelet turnoverHealthy controlsART patientsTreatment responsePrimary myeloproliferative disordersElevated platelet countSymptoms of thrombosisAspirin therapyRecurrent thrombosisThrombotic complicationsAspirin treatmentArterial thrombosisDVT patientsThrombotic riskTransient thrombocytosisThrombosis riskDeep veinsSecondary thrombocytosisAbsolute countsMyeloproliferative disordersThrombosisDifferences in Platelet α-granule Release between Normals and Immune Thrombocytopenic Patients and between Young and Old Platelets
Rinder HM, Tracey JB, Recht M, DeCastro L, Rinder CS, McHugh C, Smith BR. Differences in Platelet α-granule Release between Normals and Immune Thrombocytopenic Patients and between Young and Old Platelets. Thrombosis And Haemostasis 1998, 80: 457-462. PMID: 9759627, DOI: 10.1055/s-0037-1615229.Peer-Reviewed Original ResearchConceptsImmune thrombocytopenic purpuraThrombin receptor agonist peptideAlpha-granule releaseITP patientsOld plateletsThrombocytopenic patientsImmune thrombocytopenic patientsPlatelet α-granule releaseΑ-granule releaseNormal human controlsMaintenance of hemostasisControl RPSerious bleedingThrombocytopenic purpuraMegakaryocytic hypoplasiaPatient groupReticulated plateletsNormal controlsPatientsPlatelet responseAgonist peptideYoung plateletsPlateletsHemostatic activityCD62PPeripheral blood progenitor cell cycle kinetics following priming with pIXY321 in patients treated with the "ICE" regimen.
Murren JR, Gollerkeri A, Anderson S, Lutzker S, Del Prete S, Zelterman D, Garrison L, Smith B. Peripheral blood progenitor cell cycle kinetics following priming with pIXY321 in patients treated with the "ICE" regimen. The Yale Journal Of Biology And Medicine 1998, 71: 355-65. PMID: 10527363, PMCID: PMC2578930.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic Combined Chemotherapy ProtocolsCarboplatinCarcinoma, Non-Small-Cell LungCarcinoma, Small CellCell CycleEtoposideFemaleGranulocyte-Macrophage Colony-Stimulating FactorHematopoietic Stem CellsHumansIfosfamideInterleukin-3Lung NeoplasmsMaleMiddle AgedNeutropeniaRecombinant Fusion ProteinsSurvival RateTreatment OutcomeConceptsCell lung cancerPeripheral bloodLung cancerGrowth factorProgenitor cellsDay 1Non-small cell lung cancerSmall cell lung cancerCycle-specific chemotherapyCell cycle distributionHematopoietic growth factorsProgenitor cell cyclingHematologic recoveryPartial responseHematopoietic progenitor cellsCell cycle kineticsPreclinical dataCertain growth factorsSpecific chemotherapySubcutaneous injectionTransient fallCycling progenitor cellsReduced riskPatientsMarrow compartment
1994
B-Cell Precursor Bone Marrow Reconstitution After Bone Marrow Transplantation
Leitenberg D, Rappeport J, Smith B. B-Cell Precursor Bone Marrow Reconstitution After Bone Marrow Transplantation. American Journal Of Clinical Pathology 1994, 102: 231-236. PMID: 8042594, DOI: 10.1093/ajcp/102.2.231.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAntigens, CDB-LymphocytesBlotting, SouthernBone MarrowBone Marrow CellsBone Marrow TransplantationChildChild, PreschoolClone CellsFemaleFlow CytometryFluorescent Antibody TechniqueGene Rearrangement, B-Lymphocyte, Heavy ChainHematopoietic Stem CellsHumansImmunophenotypingInfantKineticsMaleMiddle AgedNeprilysinConceptsBone marrow transplantationMarrow transplantationB cell subsetsBone marrow reconstitutionB cell precursorsSurface antigenic phenotypeImmature B cellsImmunoglobulin gene rearrangementsHumoral immunodeficiencyMonoclonal gammapathyMarrow reconstitutionAntigenic phenotypeB cellsTransplantationGene rearrangementsMarked increaseLeukemia lymphoblastsCellsPatientsGammapathyImmunodeficiencyMarrowCD34ReconstitutionMonthsNoninvasive measurement of platelet kinetics in normal and hypertensive pregnancies
Rinder H, Bonan J, Anandan S, Rinder C, Rodrigues P, Smith B. Noninvasive measurement of platelet kinetics in normal and hypertensive pregnancies. American Journal Of Obstetrics And Gynecology 1994, 170: 117-122. PMID: 8296812, DOI: 10.1016/s0002-9378(94)70395-7.Peer-Reviewed Original ResearchConceptsPregnancy-induced hypertensionNormal pregnancyPlatelet countPlatelet kineticsImmune platelet destructionSerum antiplatelet antibodiesPlatelet-associated immunoglobulinsLarge prospective studiesNormal nonpregnant womenOnset of symptomsPlatelet productionHypertensive pregnanciesAntiplatelet antibodiesNonpregnant womenClinical courseNulliparous womenWeeks' gestationPlatelet destructionProspective studyPregnant womenClinical signsPlatelet valuesSerial measurementsBlood samplesPlatelet decrease
1993
Determination of the percentage of thiazole orange (TO)‐positive, “reticulated” platelets using autologous erythrocyte TO fluorescence as an internal standard
Bonan J, Rinder H, Smith B. Determination of the percentage of thiazole orange (TO)‐positive, “reticulated” platelets using autologous erythrocyte TO fluorescence as an internal standard. Cytometry 1993, 14: 690-694. PMID: 8404376, DOI: 10.1002/cyto.990140615.Peer-Reviewed Original ResearchReticulated platelets in the evaluation of thrombopoietic disorders.
Rinder HM, Munz UJ, Ault KA, Bonan JL, Smith BR. Reticulated platelets in the evaluation of thrombopoietic disorders. Archives Of Pathology & Laboratory Medicine 1993, 117: 606-10. PMID: 8503732.Peer-Reviewed Original ResearchConceptsImmune platelet destructionImmune thrombocytopeniaPlatelet destructionNormal subjectsImmune thrombocytopenic purpuraThird of patientsSubset of patientsPlatelet determinationAbsence of megakaryocytesPlatelet-associated IgGChemotherapy-induced thrombocytopeniaInvasive diagnostic testsPeripheral blood plateletsFlow cytometric assayIgG levelsThrombocytopenic purpuraReticulated plateletsImmune destructionPlatelet valuesPatientsPlatelet IgGBone marrowThrombocytopeniaIgG dataLaboratory diagnosis
1991
Selective Depletion of Bone Marrow T Lymphocytes With Anti-CD5 Monoclonal Antibodies: Effective Prophylaxis for Graft-Versus-Host Disease in Patients With Hematologic Malignancies
Antin J, Bierer B, Smith B, Ferrara J, Guinan E, Sieff C, Golan D, Macklis R, Tarbell N, Lynch E, Reichert T, Blythman H, Bouloux C, Rappeport J, Burakoff S, Weinstein H. Selective Depletion of Bone Marrow T Lymphocytes With Anti-CD5 Monoclonal Antibodies: Effective Prophylaxis for Graft-Versus-Host Disease in Patients With Hematologic Malignancies. Blood 1991, 78: 2139-2149. PMID: 1717080, DOI: 10.1182/blood.v78.8.2139.2139.Peer-Reviewed Original ResearchConceptsAnti-CD5 MoAbHigh-risk patientsGraft failureHost diseaseHematologic malignanciesT cellsEpstein-Barr virus-associated lymphoproliferative disorderBone marrowActuarial event-free survivalBone marrow T lymphocytesAnti-CD5 monoclonal antibodyDiagnosis of myelodysplasiaMarrow T lymphocytesEvent-free survivalLow-risk patientsLate graft failureTotal body irradiationSignificant risk factorsRisk of relapseMajor histocompatibility complexActuarial survivalAcute graftAcute GVHDChronic GVHDEvaluable patients
1990
Cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation in refractory Hodgkin's disease and non-Hodgkin's lymphoma: a dose-finding study.
Wheeler C, Antin JH, Churchill WH, Come SE, Smith BR, Bubley GJ, Rosenthal DS, Rappaport JM, Ault KA, Schnipper LE. Cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation in refractory Hodgkin's disease and non-Hodgkin's lymphoma: a dose-finding study. Journal Of Clinical Oncology 1990, 8: 648-56. PMID: 2313334, DOI: 10.1200/jco.1990.8.4.648.Peer-Reviewed Original ResearchConceptsAutologous bone marrow transplantationMaximum-tolerated doseBone marrow transplantationRelapsed lymphomaComplete responseMarrow transplantationDose levelsVP-16Refractory Hodgkin's diseaseTreatment-related mortalityDose-finding studyAssessable patientsAcceptable toxicityConditioning regimenInterstitial pneumonitisHodgkin's diseaseResidual diseaseHodgkin's lymphomaPatient populationDisease progressionHigh dosePatientsLymphomaDiseaseCBVDepletion of bone marrow T-lymphocytes with an anti-CD5 monoclonal immunotoxin (ST-1 immunotoxin): effective prophylaxis for graft-versus-host disease.
Antin JH, Bierer BE, Smith BR, Guinan EC, Provost MM, Ferrara J, Macklis RM, Tarbell NJ, Blythman H, Bouloux C. Depletion of bone marrow T-lymphocytes with an anti-CD5 monoclonal immunotoxin (ST-1 immunotoxin): effective prophylaxis for graft-versus-host disease. Progress In Clinical And Biological Research 1990, 333: 207-15. PMID: 1689852.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAntibodies, MonoclonalAntigens, CDAntigens, DifferentiationBone MarrowBone Marrow CellsBone Marrow TransplantationCD5 AntigensChildChild, PreschoolCombined Modality TherapyCyclophosphamideCytarabineDrug EvaluationGraft vs Host DiseaseHumansImmunotoxinsLeukemiaMiddle AgedMyelodysplastic SyndromesRicinRisk FactorsT-LymphocytesWhole-Body Irradiation